CytomX Therapeutics Presents Preclinical Profile of EpCAM-directed Antibody Drug Conjugat… Introduction CytomX Therapeutics recently unveiled the promising preclinical profile of their innovative cancer treatment, CX-2051. This novel drug is specifically designed for the treatment of EpCAM-expressing cancers by effectively targeting the tumor cells with a topoisomerase-1 inhibitor payload. The preclinical data has shown impressive results,…

Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy Introduction Caribou Biosciences has recently made a groundbreaking announcement regarding the FDA clearance of the Investigational New Drug (IND) application for CB-012, an allogeneic anti-CLL-1 CAR-T cell therapy. This innovative therapy combines genome editing techniques with checkpoint disruption and…

In yet another round of financial collabs, Mastercard has announced yet more partnerships Mastercard and Consumer Empowerment In yet another round of financial collabs, Mastercard has announced yet more partnerships. Instacart and Peacock have joined forces with the credit card giant to provide unparalleled everyday value and convenience to discerning consumers. Mastercard would have us…

Middle East Conflict Impacting Markets Introduction As we head into European trading, major currencies are holding steady while commodities are seeing significant fluctuations due to the ongoing violence in the Middle East. The Israel-Hamas conflict is intensifying, driving up prices of gold and oil as investors seek safe-haven assets. This week, gold is poised to…

Breaking Down Aware’s Designation in the Biometric Digital Identity Market Report What Does It Mean to Be Named a “Catalyst”? According to the latest Biometric Digital Identity Prism Report, Aware, Inc. has been recognized as a true industry “Catalyst” for its disruptive innovations and accelerated growth in the biometrics market. This designation sets Aware apart…